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A vaccine to protect against COVID-19 is urgently needed. Such a vaccine 
should efficiently induce high-affinity neutralizing antibodies which neutralize 
SARS-CoV-2, the cause of COVID-19. However, there is a concern with both 
vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 
immunopotentiation following infection after vaccination. Here, we review the 
anticipated characteristics of a COVID-19 vaccine to avoid vaccine associated 
eosinophil immunopathology. 
 
COVID-19 is a new infectious disease caused by a Coronavirus, SARS-CoV-2 [1]. The 
virus exhibits high infectivity and can cause a broad spectrum of symptoms and 
severities [2]. To limit the damage of COVID-19, primary efforts focus on confinement, 
with physical distancing, wearing face masks and hygiene measures [3]. However, 
although these measures help against viral spread, they cause limitations in our 
personal and professional lives. Moreover, there is a constant risk of viral outbreaks 
with severe consequences for health and economics. Therefore, rapid immunization 
of the world’s population against Severe Acute Respiratory Syndrome (SARS)-Corona 
Virus (CoV)-2 is needed and vaccines are currently being developed world-wide [4]. 
There are several strategies to develop a vaccine such as live-attenuated or 
inactivated viruses, viral vector-containing nanoparticles or virus-like particles, subunit 
components, proteins/peptides, RNA, DNA or even viable cells. These strategies are 
reviewed elsewhere [4]. In this article, we would like to point out the risk of eosinophil-
associated immunopathology following infection after SARS-CoV-2 vaccination as well 
as strategies for its prevention. 
 
COVID-19 and eosinophils 
Eosinophils represent a subpopulation of granulocytes which can mediate 
immunopathology in eosinophilic diseases such as bronchial asthma, eosinophilic 
esophagitis, and hypereosinophilic syndromes [5]. Eosinophils are believed to exhibit 
anti-bacterial and anti-viral effector functions as well as protecting against parasites 
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[6,7]. Although rhinovirus (RV), respiratory syncytial virus (RSV), and influenza virus 
(IFV) are common triggers of viral-induced asthma exacerbation, neither SARS-CoV-
1 nor SARS-CoV-2 have been identified as risk factors for asthma exacerbations [8,9]. 
Interestingly, COVID-19 patients exhibited eosinopenia while eosinophil levels 
increased in association with improved clinical status [9]. Moreover, in a patient with 
COVID-19, a lymphocytic infiltration of the lungs was observed, whereas no eosinophil 
infiltration was detected [10]. Taken together, although the available data are very 
limited, eosinophils do not seem to play either a protective or pathogenic role in 
COVID-19 under normal circumstances. 
But how about the role of eosinophils during Coronavirus vaccination? SARS-CoV-1 
vaccines have been shown to induce pulmonary eosinophilia in ferrets [11], monkeys 
[11], and mice [12] after viral challenge. Eosinophil-associated type 2 inflammation 
also occurred with SARS-CoV-1 reinfection in monkeys [13]. Eosinophil-associated 
pulmonary disease was also seen subsequent to infection after RSV vaccination [14]. 
Therefore, there is the possibility that SARS-CoV-2 vaccines might cause a similar 
vaccine-associated immunopathology. 
 
Immune responses in association with Coronavirus vaccination 
The most promising strategy for reaching immunity against COVID-19 is to induce the 
production of virus-neutralizing antibodies (Figure 1). Such antibodies usually block 
the interaction of the virus with its cellular receptor. The cellular receptor of SARS-
CoV-2 is the angiotensin-converting enzyme 2 (ACE2) [15]. Therefore, the primary 
immune mechanism for avoiding infection seems to be by blocking viral attachment to 
ACE2. Indeed, most COVID-19 vaccine candidates follow this strategy [16]. The 
obvious isotype to be induced is IgG, particularly the protective IgG1 and IgG3 
subclasses. However, since the virus targets mucosal surfaces, IgA induction might 
also be beneficial. The formulation of the vaccine candidate with Toll-like receptor 
(TLR) 7/8 and TLR9 ligands to the vaccine might promote IgA production [17,18] and, 
in addition, may favor type 1 immune responses (Figure 1) [19]. 
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To obtain specific antibody production, B cells require “help” from CD4+ T cells. The 
induction of CD4+ T helper cells is often not rate limiting in vaccination, most likely 
because already low numbers of these cells are sufficient for antibody production. 
Nevertheless, vaccination low-responders often fail to mount IgG responses due to 
insufficient CD4+ T cell “help”. Since T cell help can be provided by CD4+ T cells with 
other antigen specificities, vaccines can be supplemented with microbial proteins or 
peptides to which most humans are already immunized [20]. The immune response to 
these antigens will be strong because boosting of previously primed and established 
CD4+ T cells is more efficient than priming. Such microbial antigens may also skew the 
immune response towards T helper type 1 polarization (Figure 1) [19]. 
A type 1 immune response might also be attained by viral vectors or innate stimulators 
with type 1 polarization capabilities [21-23]. For instance, nanoparticles and virus-like 
particles can be designed to contain molecules that stimulate innate immunity to 
enhance T helper 1 and to block T helper 2 polarization [24]. 
The type of the T helper immune response may also depend on the antigen. 
Immunization with inactivated SARS-CoV-1 causes eosinophilic infiltration following 
viral re-exposure in mice [25]. Immunization with the whole spike (S) protein, which is 
responsible for binding to ACE2, also triggered type 2 inflammation including 
eosinophilia after viral challenge in mice [11]. In contrast, at least in the case of SARS-
CoV-1, immunization with the so-called receptor binding domain (RBD), which is a 
particular part within the S protein, induced neutralizing antibodies in the absence of a 
type 2 immune response (Figure 1) [26]. 
Increased immune pathology may also occur by antibodies induced by the vaccine 
(Figure 2). For example, an antibody enhancement of infection may occur when 
antibodies promote viral uptake via Fc receptors. However, there is no evidence that 
such mechanism occurs with SARS-CoV-1 [27]. On the other hand, antibodies may 
also activate immunoreceptor tyrosine-based activation motifs (ITAMs) within the 
cytoplasmic domain of Fc receptors, resulting in increased secretion of pro-
inflammatory cytokines by macrophages and dendritic cells. Such a scenario, 
however, requires a high virus load which is unlikely to occur if vaccine-induced 
neutralizing antibodies are present. Therefore, antibody-dependent enhancement is 
not expected to cause problems for COVID-19 but eosinophil-mediated 
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immunopathology following SARS-CoV-2 vaccination and infection may be at the heart 
of the problem (Figure 2). 
Taken together, COVID-19 vaccines should induce high-affinity neutralizing 
antibodies. Moreover, they should polarize the T cell response towards type 1 immunity 
and avoid the stimulation of cytokines which induce T helper 2 immunity. To avoid type 
2 inflammatory responses, a careful selection of the vector and the antigen are 
required. The addition of TLR ligands and other molecules stimulating type 1 immunity 
might be helpful with respect to sufficient CD4+ T cell help for antibody production as 
well as suppressing unwanted type 2 immunity causing eosinophilia. It should be 
noted, however, that it is only partially possible to predict vaccine efficacy and safety 
[28]. Due to its urgency, COVID-19 vaccination should be given the highest priority. 
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Fig. 1.  An illustrated presentation of the anticipated type 1 and type 2 immune 
responses by SARS-CoV-2, the spike (S) protein and its receptor binding domain 
(RBD). Based on information about SARS-CoV-1, the whole virus and the complete S 
protein induce type 2 immune responses. In contrast, RBD does not induce type 2 
inflammation. It is suggested that a COVID-19 vaccine should contain the RBD and 
additional Th1-promoting molecules (dashed box). High-affinity SARS-CoV-2 
neutralizing antibodies are the best protection against virus-induced type 2 eosinophilic 
inflammation upon re-challenge. 
 
Fig. 2.  Vaccination may enhance disease by induction of IgG antibodies (left) or 
Th2 cells (right). IgG antibodies may enhance infection if the cellular target of infection 
expresses Fc-receptors (a). Alternatively, IgG antibodies may enhance antigen 
presentation, by targeting viral particles to professional antigen-presenting cells 
enhancing inflammation (b). Th2 cells may recruit eosinophils to the lung, also causing 
enhanced infection (c). As SARS-CoV-2 does not infect Fc-receptor expressing cells 
and viral load is expected to be reduced in vaccinated individuals, IgG antibodies are 
not expected to cause enhanced disease, in particular not neutralizing antibodies. Th2 
cell-induced eosinophilia, may, however, be a major concern and induction of Th2 cells 
by vaccination therefore should be avoided. 
 
